Replies to post #9395 on Synaptogenix Inc (SNPX)

[XenaLives]

Um.. both Anavex and Neurotrope are in phase two.

There is no "hands down" anything at this point.

Neurotrope has a placebo P2 which is not required in a safety trial.

Anavex has five years of safety data.

Anavex has two trials reading out this year which will give additional data. The largest trial, in Parkinson's dementia, has had investigators requesting to extend the trial before it is fully enrolled. Something must be going on. This is a placebo controlled trial. If investigators are seeing results so obvious that they believe the trial needs to be extened the placebo is moot and the P2a in Alzheimer's is corroborated.

The results from the Parkinson's trial could be strong enough for Anavex to gain provisional approval in Australia before the end of the year.

[runncoach]

It's a sad place for the competition to be in when they have to hope for other company failures because they are so far behind. It is what it is and that can't be changed. Win, lose, or draw ntrp has chosen quickest path to market and thats going to bother some.